Copeland Capital Management’s AstraZeneca AZN Stock Holding History

Copeland Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-21	Closed	-$2.76K	–	274
2023 Q4	$2.76K	Hold	21	–	–	﹤0.01%	257
2023 Q3	$2.78K	Hold	21	–	–	﹤0.01%	258
2023 Q2	$2.93K	Hold	21	–	–	﹤0.01%	277
2023 Q1	$3K	Hold	21	–	–	﹤0.01%	234
2022 Q4	$3K	Hold	21	–	–	﹤0.01%	238
2022 Q3	$2K	Hold	21	–	–	﹤0.01%	250
2022 Q2	$3K	Hold	21	–	–	﹤0.01%	227
2022 Q1	$3K	Buy	+21	New	+$2.52K	﹤0.01%	236

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Copeland Capital Management's AZN Position: Q1 2024 in Review

Copeland Capital Management sold out of AstraZeneca (AZN) in Q1 2024, closing a stake of 21 shares — an estimated $2.76K sold.

Copeland Capital Management first reported a position in AZN in Q1 2022 and held it in 8 quarters. The position peaked at $3K in Q1 2023. 1,142 funds tracked by Wall St. Rank hold AZN as of Q1 2024.

Copeland Capital Management reported no remaining AstraZeneca position as of Q1 2024 after selling out during the quarter.
Copeland Capital Management sold 21 AstraZeneca shares in Q1 2024, an estimated $2.76K.
Copeland Capital Management first reported a position in AstraZeneca in Q1 2022 and held it in 8 quarters.
Copeland Capital Management's AstraZeneca position peaked at $3K in Q1 2023.
1,142 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2024.

Based on Copeland Capital Management's 13F filing for Q1 2024, filed 19 Apr 2024.